Biosimilars and similar biologics (for injectable GLP-1 analogues such as liraglutide, dulaglutide, and semaglutide) if companies can demonstrate comparability in structure, function, and clinical performance.[11] This framework is what enabled Indias earlier waves of affordable insulin, cancer drugs, and biologics and it is now being replicated for GLP-1 therapies
Other rows cover inadequate caloric or protein intake, poor hydration, baseline anemia or low iron stores, sleep disruption, and concurrent illness or high stress, each mapped to how it shifts fatigue risk
Between months 46, weight loss continues at a slower steady pace (typically 0.51.5 pounds per week) and plateaus become more common, requiring patience and consistent lifestyle adherence
10.1016/j.biopha.2018.10.092 143 MarcinkiewiczJ